A citation-based method for searching scientific literature

Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
100




Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
René Rodríguez-Gutiérrez, Victor M Montori. Circ Cardiovasc Qual Outcomes 2016
74
100

Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications.
Elisa Dal Canto, Antonio Ceriello, Lars Rydén, Marc Ferrini, Tina B Hansen, Oliver Schnell, Eberhard Standl, Joline Wj Beulens. Eur J Prev Cardiol 2019
75
100


Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter Gaede, Pernille Vedel, Nicolai Larsen, Gunnar V H Jensen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2003
100


Intensive glycemic control in the ACCORD and ADVANCE trials.
Robert G Dluhy, Graham T McMahon. N Engl J Med 2008
266
100


Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais. N Engl J Med 2000
100


Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.
Elaine Chow, Alan Bernjak, Scott Williams, Robert A Fawdry, Steve Hibbert, Jenny Freeman, Paul J Sheridan, Simon R Heller. Diabetes 2014
229
100



The effect of guideline revisions on vascular complications of type 2 diabetes.
Ralph Heijmans, Sunny S Singh, Aloysius G Lieverse, Eric J G Sijbrands, Mandy van Hoek. Ther Adv Endocrinol Metab 2019
3
100

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
100


Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2018
287
100

Clinical implications of the ACCORD trial.
S Genuth, F Ismail-Beigi. J Clin Endocrinol Metab 2012
38
100

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
271
100

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Sophia Zoungas, John Chalmers, Bruce Neal, Laurent Billot, Qiang Li, Yoichiro Hirakawa, Hisatomi Arima, Helen Monaghan, Rohina Joshi, Stephen Colagiuri,[...]. N Engl J Med 2014
352
100

Intensive Glucose Control and Type 2 Diabetes - 15 Years On. Reply.
Peter D Reaven, Rodney A Hayward, Jin Zhou. N Engl J Med 2019
2
100

Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.
Robert J Chilton, Kathleen M Dungan, Jay H Shubrook, Guillermo E Umpierrez. Prim Care Diabetes 2020
4
100

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
177
100

16
100


Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Scott C Thomson, Volker Vallon. Am J Cardiol 2019
16
100

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
100

Thiazolidinediones.
Hannele Yki-Järvinen. N Engl J Med 2004
100


Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
100

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
100

GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Miriam Longo, Paolo Chiodini, Katherine Esposito. Diabetes Obes Metab 2019
66
100

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
100


Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
100

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
100

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
100

Long-term effects of intensive glucose lowering on cardiovascular outcomes.
Hertzel C Gerstein, Michael E Miller, Saul Genuth, Faramarz Ismail-Beigi, John B Buse, David C Goff, Jeffrey L Probstfield, William C Cushman, Henry N Ginsberg, J Thomas Bigger,[...]. N Engl J Med 2011
665
100

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
251
100

Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
David Z Cherney, Ayodele Odutayo, Ronnie Aronson, Justin Ezekowitz, John D Parker. J Am Coll Cardiol 2019
28
100


Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
100

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Donna H Ryan, Ildiko Lingvay, Helen M Colhoun, John Deanfield, Scott S Emerson, Steven E Kahn, Robert F Kushner, Steve Marso, Jorge Plutzky, Kirstine Brown-Frandsen,[...]. Am Heart J 2020
23
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.
Suzanne V Arnold, James A de Lemos, Robert S Rosenson, Christie M Ballantyne, Yuyin Liu, Katherine E Mues, Shushama Alam, Mary Elliott-Davey, Deepak L Bhatt, Christopher P Cannon,[...]. Circulation 2019
42
100

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Nikolaus Marx, Darren K McGuire, Vlado Perkovic, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Jyothis T George, Julio Rosenstock. Diabetes Care 2017
27
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.